埃法维伦兹
病毒载量
杜鲁特格拉维尔
拉米夫定
养生
内科学
医学
逻辑回归
队列
抗逆转录病毒疗法
人类免疫缺陷病毒(HIV)
病毒学
病毒
慢性肝炎
作者
Vanessa Aracele Rodrigues,Maria das Graças Braga Ceccato,Juliana de Oliveira Costa,Celline Cardoso Almeida-Brasil,Micheline Rosa Silveira,Edna Afonso Reis
标识
DOI:10.1080/09540121.2022.2072802
摘要
Levels of adherence to antiretroviral therapy (ART) can affect the likelihood of viral suppression differentially among ART regimens. In this prospective cohort conducted in Belo Horizonte, Brazil, we included 354 individuals who initiated ART containing tenofovir disoproxil fumarate/lamivudine/efavirenz in fixed-dose combination (TDF/3TC/EFV) or tenofovir disoproxil fumarate/lamivudine associated with dolutegravir (TDF/3TC + DTG). Viral suppression (viral load <50 copies/mL) was evaluated within six months of follow-up at different adherence levels and by therapeutic regimen. Adherence was measured by the Proportion of Days Covered (PDC) and classified into low (≤84%), intermediate (85-89%) or high (≥90%). The association between viral suppression, adherence levels, and other explanatory variables was analyzed using chi-square and multivariable logistic regression. Viral suppression was achieved by 76.0% of individuals and was more frequent among those who achieved higher levels of adherence (high adherence: 79.3%, intermediate: 71.4% and low: 45.2%), those on TDF/3TC + DTG, and those who had viral load ≤100,000 copies/mL at the onset of treatment (p < 0.05). Moreover, individuals on TDF/3TC + DTG had an approximately 90% probability of achieving viral suppression at intermediate adherence levels. These results add new insights on the possibility of lower adherence levels for contemporary antiretroviral regimens currently used as first-line therapy worldwide.
科研通智能强力驱动
Strongly Powered by AbleSci AI